Navigation Links
Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes
Date:12/2/2008

Randomized Comparator Study to Evaluate Efficacy of Commercially Available Hypomethylating Agents

WOODCLIFF LAKE, N.J., Dec. 2 /PRNewswire/ -- Eisai Corporation of North America today announced that it plans to initiate the first clinical trial evaluating the activity of Dacogen(R) (decitabine for injection) compared to Vidaza(R) (azacitidine) in adult patients with intermediate-1, intermediate-2 or high-risk myelodysplastic syndromes (MDS), a potentially life-threatening group of bone marrow diseases that limit the production of functional blood cells. The head-to-head trial will be conducted in the United States and will directly compare Dacogen(R) to Vidaza(R) with a primary endpoint of complete response rate (including marrow complete response).

"Previous to the introduction of the hypomethylating agents, supportive care was the only treatment option for patients living with MDS," said Dr. Hagop M. Kantarjian, chairman of the Leukemia Department and professor of medicine, University of Texas M.D. Anderson Cancer Center. "This study, for the first time, will provide physicians with important information to understand how these two agents compare when treating patients with MDS, who currently have a generally poor prognosis, with life expectancies shorter than those with lung cancer."

Study Design

This randomized, multi-center, open-label study will be conducted among 228 adult patients with intermediate-1, intermediate-2 and high-risk MDS. Patients will be randomized on a 1:1 ratio to either Dacogen(R) or Vidaza(R). Each treatment arm will be stratified by IPSS risk group and type of MDS (primary vs. secondary).

The study's primary objective is to compare the complete response rates, including bone marrow response rates, for Dacogen(R) versus Vidaza(R).

"Findings from this trial could help clarify the fundament
'/>"/>

SOURCE Eisai Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
2. Eisai Inc. and the Alzheimers Association Introduce the C.A.R.E. Pharmacy Award and Call for Nominations
3. Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
4. Eisai Inc. Supports Acting Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
5. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
6. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
7. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
8. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
9. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
10. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
11. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... Thermi, a ... is proud to announce South Korea’s Ministry of Food and Drug Safety ... most sought-after radio frequency thermotherapy technology available in United States, South Korea, Thailand, ...
(Date:8/30/2015)... ... August 30, 2015 , ... ProTrailer Party is a new and exciting ... 30 styled and detailed presets, allowing FCPX users to immerse the audience into ... will help film makers save time while adding professional titles to every project. , ...
(Date:8/30/2015)... ... 2015 , ... Intellitec Solutions, based in Wilmington, DE, will ... & 6th in San Antonio, TX. Dedicated to bringing long term and post-acute ... over the country come to share the latest and greatest in healthcare technologies, ...
(Date:8/30/2015)... ... 30, 2015 , ... Lizzie’s Lice Pickers , a company that offers ... is currently offering lice head checks for just $10, which is a significant discount ... discount on their lice treatment products. “With kids returning to school, it is very ...
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... ... Vice President Jeff Fernandez will lead the expansion of global cosmeceutical and skin ... skin care experience having spent the last 25 years working in operations, purchasing ...
Breaking Medicine News(10 mins):Health News:Thermi Heats Up South Korea Announcing Global Expansion with NewRegulatory Approvals for ThermiRF™ 2Health News:FCPX Effects Developer Releases ProTrailer Party for Final Cut Pro X 2Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2Health News:Lizzie’s Lice Pickers Announces Back to School Head Check Special and Discounted Lice Treatment Products 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2
... 21 Meridian International,Center today announced that its ... M.D. will lead Meridian,s new Global Health,Program. The ... of Meridian,s,programs that include world affairs public briefings ... and arts and,cultural activities., "Today, 79% of ...
... SinoFresh HealthCare,Inc. (OTC Bulletin Board: SFSH), a ... today announced that the company,s CEO,Charles Fust, is ... Show., The interview gives viewers an overview ... latest press release., To ...
... It means different things to youngsters, so sex ed ... THURSDAY, Aug. 21 (HealthDay News) -- One reason why ... activity is because abstinence can mean different things to ... University of Washington study. , Teens, attitudes and intentions ...
... vaccination leading to increase, CDC report says , , THURSDAY, ... vaccinate children seems to be behind the highest rate ... Thursday. , Between Jan. 1 and July 31 of ... the United States, many of them among children whose ...
... League Baseball World Series, CHICAGO, Aug. 20 ... the winner of its annual slogan contest today,and ... coaches and parents,about tobacco addiction and the health ... tobacco. This year,s slogan contest winner is,Joe Reck, ...
... recently enacted Medicare Improvement Law immediately affects the operations ... ... nationwide, PORTLAND, Ore., Aug. 20 ... 6331, creating new legislation,protecting Medicare beneficiaries, they also established stricter,requirements for ...
Cached Medicine News:Health News:Former U.S. Assistant Surgeon General, Dr. Susan Blumenthal, to Lead Meridian International Center's Global Health Program 2Health News:[video] Charles Fust, CEO of SinoFresh HealthCare, Inc. Discusses Preliminary Test Results From In Vivo Pilot Study on WallSt.net's 3-Minute Press Show 2Health News:Abstinence-Only Programs Fall Short of Teens' Needs 2Health News:Measles Cases Highest Since 1996 2Health News:Measles Cases Highest Since 1996 3Health News:Slogan Contest Educates Young Baseball Players About the Dangers of Tobacco Use 2Health News:Medicare Advantage Plans Struggle to Comply With New Federal Law 2
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on ... their offering. Developed by Novo Nordisk, ... is an important drug for the treatment of ... a fast- acting insulin analog, starts working fast ...
(Date:8/28/2015)... Aug. 28, 2015 Perrigo Company plc ("Perrigo") ... Mylan N.V. ("Mylan") (NASDAQ: MYL ) shareholder vote ... "Our views of Mylan,s offer to Perrigo shareholders ... on our Board,s careful reflection of the value available ... limited choices that Mylan has allowed its shareholders to ...
(Date:8/28/2015)... The report "Eubiotics Market by Type (Probiotics, Prebiotics, ... Aquaculture), & by Region ( North America , ... and Rest of the World) - Global Trends and Forecast ... was valued at USD 4.62 Billion in 2014 and is ... CAGR of 7.4% from 2015 to 2020. ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... 2007 - Cytogen,Corporation (NASDAQ: CYTO) reported updated ... evaluating QUADRAMET(R) (samarium Sm-153,lexidronam injection) in combination ... with relapsed,multiple myeloma. Data from 33 patients ... 1 Trial of Bortezomib (Vel) and Samarium,(Sam) ...
... achieved with VELCADE, lenalidomide,and dexamethasone , ,KOS, ... (Nasdaq: MLNM) today reported on the,presentation of ... based,therapies that showed consistently high survival and ... newly diagnosed,multiple myeloma (MM) patients. These data ...
Cached Medicine Technology:Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8
Double-ended. 3 mm x 5 mm curette end and 3 mm spatula end....
Double-ended. 6 mm x 9 mm and 6 mm x 11 mm tips....
2 mm tip....
4 mm x 6 mm dissector end with shaft marked at 10 mm, 20 mm, 30 mm from tip. 6 mm wide curved elevator. Round knurled handle....
Medicine Products: